Game,

Your posting presents an accurate picture of why IMO Cardiogenics' share price has fallen.

The conclusion I have reached is broader in nature than yours - I conclude a lack of competent management is at play within Cardiogenics. In a nutshell, promising science is being undermined by an incompetent management team that IMO includes both the Board of Directors and the Company's Executive Officers.

I am hopeful that if Cardiogenics is able to complete another PIPE, the investor will require or place an experienced professional executive onto the management team to play a leading role in the day to day management of the company.

Ante